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The pharmacokinetics of cefotiam were investigated after intravenous adminis-
tration of 1 g to 2 healthy volunteers with normal renal function and to 16 patients
whose creatinine clearance ranged from 4-7 to 01 1/h (78 to 1-66 ml/min). The
elimination half-life varied from 1 • 1 h in normal subjects to 13 h in patients and
the total plasma clearance from 21 to 0-6 1/h (350 to 10 ml/min). The urinary
recovery decreased from 62% of the dose in normal subjects to 1-1% in patients,
and the renal clearance from 15 to 0-03 1/h (250 to 0-5 ml/min). Plasma and renal
clearances of cefotiam correlated well with the creatinine clearance.
The dosage schedule for cefotiam in patients with normal renal fiinction can
be used in the presence of renal failure when the creatinine clearance is equal to
or greater than 1 1/h (16-6 ml/min). For patients whose creatinine clearance is less
than 1 1/h, the dose must be decreased to 75% of that for a patient with normal
renal function only when it is given every 6 or 8 h.
Introduction
Cefotiam is a new semisynthetic cephalosporin for parenteral administration. It is
highly potent against a broad spectrum of Gram-positive and Gram-negative bac-
teria. This drug is predominantly excreted via the kidneys in healthy volunteers
(Daschner et al, 1982). The present study was designed to investigate the effect of
renal dysfunction on the pharmacokinetics of cefotiam, and to determine if any
adjustment of the dosage regimen is necessary to avoid excessive accumulation in
the presence of renal impairment.
Materials and methods
Selection of subjects
This study was performed on two healthy male volunteers with normal renal func-
tion and on 16 patients with various degrees of renal impairment. Every subject was
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Table I. Pharmacokinetic parameters of cefotiam in normal subjects and in patients with
various degrees of renal impairment after a single intravenous dose of 1 g
Case
no.
Creatinine
clearance
(1/h)
Maximum
plasma
concentration
(umol/1)*
Patients with renal impairment
1
2
3
4
5
6
7
8
9
10
11
12
13
14t
15
16
0 1
0-3
0-3
0-3
0-4
0-4
0-6
0-9
1-2
1-5
2-3
2-3
3-3
3-8
4-3
4-7
189
303
315
211
268
245
182
176
300
189
257
304
299
202
179
194
Volunteers with normal renal function
1
2
7-7
8-3
190
160
a
110
130
3-9
31
3-2
3-5
5-2
50
4-2
2-6
1-8
1-9
2-6
—
1-9
20
1-3
0-8
Plasma
clearance
(1/h)
1-6
0-6
1-9
31
1-6
2-5
21
2 0
2-7
3-9
4-3
3-7
7-7
7-1
8 0
210
210
%of
dose
excreted
in urine
11
24
5-3
2-8
11
14
19
18
36
40
48
42
54
61
69
98
66
58
Renal
clearance
(1/h)
003
01
0 1
01
0-2
0-3
0-4
0-4
10
1-6
2-3
1-9
3-8
6-2
4-8
5-7
16
14
Non-renal
clearance
(1/h)
1-6
0-5
1-8
3 0
1-3
2-2
1-7
1-6
1-7
2-3
2-0
1-8
3-9
—
2-3
2-3
50
7-0
* 1 nmole of cefotiam = 0-5256 mg.
fPlasma concentrations could not be determined for this patient in samples collected after 2 h post
injection owing to interference from other compounds.
fully informed by the clinician on the nature of the study and agreed to participate.
Both healthy subjects, aged 23 and 30, weighed 69 kg. The age of patients (8 females
and 8 males) ranged from 33 to 60 years, their weight from 38 to 85 kg. The endo-
genous creatinine clearance (C/CT) measured over 24 h was 7-7 and 8-3 1/h in the two
healthy volunteers. In patients, C/CT was determined one week before the experiment,
and during the last 24 h of the experiment; the averages of these two values are given
as C4r in Table I, they ranged from 0-1 to 4-7 1/h.
Dosing schedule and sampling
All subjects were given a single intravenous dose of 1 g cefotiam. The drug was dis--
solved in 6 ml of sterile water for healthy subjects and in 20 ml for patients and was
injected over 1 and 3 min respectively. Normal subjects received no other medication
during the study and for eight days before. Most uraemic patients received drugs
besides cefotiam, but no other antibiotic.
Blood samples were collected into heparinized tubes before the injection and at
times 5, 15, 30 min and 1,2, 5, 10 and 24 h after drug injection. A few more samples
were taken from healthy subjects within the first 8 h post-injection. In patients with
severe renal failure, samples were also collected at 48 and 72 h. Plasma was separated
by centrifugation. Urine was collected before administration and within different
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time intervals up to 24 h for healthy volunteers (0-1, 1-2, 2-4, 4-6, 6-8, 8-10 and
10-24 h post-injection), and up to 36, 48 or 72 h for patients according to the degree
of renal dysfunction. Plasma and urine samples were stored at — 20°C until analysis.
Preliminary studies have shown that cefotiam is stable in these conditions for several
months (Lecaillon et al., 1982).
Assay procedure
Plasma and urinary concentrations of cefotiam were determined by reversed-phase
liquid chromatography (Lecaillon et al., 1982). The limits of quantitation of the
method were 0-4 uxnol/1 of plasma and 10 umol/1 of urine.
Data analysis
The following pharmacokinetic parameters were calculated:
Cmax- maximum plasma concentration determined 5 min after the end of infusion.
Cmax $$: maximum plasma concentration at the steady-state during a chronic treat-
ment calculated by the superposition technique applied to each individual plasma
profile after a 1 g dose for 6, 8 and 12 h dosing intervals.
Tf apparent elimination half-life of cefotiam in plasma determined from the
terminal log-linear segment of the plasma concentration-time curve.
C/to,: total plasma clearance calculated by the ratio dose/AUC where AUC is the
area under the plasma concentration-time curve determined by the trapezoidal rule
and extrapolated to time infinity.
C/r: renal clearance determined by the mean of the ratios AU/AAUC where AU
and AAUC are the amount of drug excreted in urine and the corresponding area
portion under the plasma concentration-time curve measured during the different
urine sampling periods.
Cl^: non-renal clearance calculated as C/nr = Cl^t - ClT.
The adjusted maintenance dose (DA) for different dosing intervals (6, 8 and 12 h)
was calculated upon the principle that the maximum plasma concentration at the
steady-state ( C ^ ss) in a renal failure patient should be the same as in a subject
with normal renal function. So Z)A in a patient X, can be expressed as a function
of the maintenance dose (DM) in a normal subject and of the C ^ i S S calculated for
the patient and for a normal subject:
Cms, ss m normal subject
(1)
Cnuw.ss"1 patient X
In normal subjects, no accumulation of cefotiam was found by simulating the
steady state plasma profiles by the superposition technique, even with adminis-
trations every 6 h. So C ^ s s in normal subjects may be taken as equal to Cm^-,
and equation (1) becomes:
Cmax m normal subject
D D
Cmtx, ss m patient X
In renal insufficient patients, C ^ was very variable from one individual to the
other (Table I). This variability was not reduced by correcting C^^ for the body
weight. In addition, C . ^ was not correlated with the degree of renal insufficiency.
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Figure 1. Examples of cefotiam plasma concentration-time profiles in subjects with normal or impaired
renal function after iv injection of 1 g. • , C/cr=0-61/h (patient 7); O, C/cr=l-21/h (patient 9);
A, C/CT=4-3 1/h (patient 15); A, C/cr=7-71/h (patient 1).
To avoid the error due to the variability of C^x, DA was calculated by using each
individual value of Cmax in each patient instead of the mean value of C ^ in normal
subjects. The equation used was:
Cnax in patient X
»" patient X
Results
Healthy volunteers
Plasma concentration-time curves showed a 3-phase decrease (Figure 1).
The pharmacokinetic parameters obtained for both volunteers are summarized in
Table I. Cefotiam was rapidly eliminated from plasma with a mean (7/^ = 21 1/h and
a mean T±= 11 h. Plasma was virtually cleared of cefotiam 8 h after dosing. The
24-h urinary excretion of unchanged cefotiam averaged 62% of the administered
dose, and 91% of this was eliminated within the first 2 h after dosing. The non-renal
clearance represented 38% of the total plasma clearance as a mean thereby suggesting
a non-renal route of elimination for unchanged cefotiam.
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Figure 2. Correlation between total plasma and renal clearances of cefotiam after administration of
1 g iv single doses to normal subjects and patients with renal dysfunction. Cltot= 1 -3 C/r+1 -60. r=0-992;
0001
Patients with renal impairment
Plasma concentrations exhibited a 3-phase decrease as in healthy subjects, but high
concentrations were maintained for a longer time as shown in Figure 1. The
pharmacokinetic parameters calculated for the 16 patients are given in Table I.
The plasma clearance decreased from 21 1/h in healthy volunteers to 0-6 1/h in
one case of severe renal insufficiency. The elimination half-life increased moderately
with the degree of renal impairment. A maximum value of 5-2 h was observed when
C/cr ranged from 4-7 to 0-4 1/h. In two patients with severe renal impairment
(C7cr=O-3 1/h) the half-life was 31 and 3-9 h. It was however prolonged to 13 and
11 h in two other patients whose Cl^ was 0-3 and 0-1 1/h respectively.
The more pronounced the renal dysfunction, the lower the urinary excretion
which fell to 11% of the dose and the higher the contribution of non-renal
elimination processes to the overall elimination of unchanged cefotiam.
Discussion
The volume of the central compartment did not seem to alter with renal function
since the maximum plasma concentration did not correlate with the degree of renal
impairment (Table I)- Consequently, the decrease of the total plasma clearance with
C/CT was essentially due to a decrease of the elimination rate constant.
The total plasma clearance is the sum of renal and non-renal clearances:
C/tot = Clr + Clnt. A linear relationship was observed between plasma and renal
clearances of patients and volunteers as illustrated in Figure 2:
C/^ = l-3C/ r+l-6(n=17, r=0-992;/><0-001).
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Figure 3. Correlation between total plasma clearance of cefotiam and creatinine clearance after admin-
istration of 1 g iv single doses to normal subjects and patients with renal dysfunction. C/tot=2-3 C/CT+0-3.
r=0-963;f><0-001.
When the total plasma clearance was plotted against the creatinine clearance
(Figure 3), the following equation of the regression line was obtained:
C/tot = 2-3C/CT+0-3 (n = 17, r=O-963; /><0001).
The correlation is not as good as that obtained for the relationship with C/r. The
high value of the slope indicates that other elimination processes than glomerular
filtration were also impaired when C/CT decreased.
Renal cefotiam and creatinine clearances were best fitted by a geometric regression
(Figure 4):
C/r = 0-7 Ckrl '* (n= 18, r=0-993; /»< 0-001).
A coefficient of correlation r=0-969, was obtained when these clearances were
fitted by a linear regression. In healthy subjects and in patients with the less impaired
renal function, the renal clearance of cefotiam consistently exceeded that of creati-
nine (Table I). This indicates that cefotiam was excreted unchanged in urine by both
glomerular filtration and tubular secretion in these subjects. The renal clearance of
cefotiam decreased more rapidly than that of creatinine to become similar or lower
than this one in patients whose C/cr was less than 2-31/h. This suggests that the tubu-
lar secretion might decrease rapidly with decreasing Ch, and that passive' tubular
reabsorption of cefotiam might also operate in patients with severe renal damage.
Such an impairment of the tubular secretion when Cb decreases was previously
reported for other cephalosporins, cefuroxime (Dalen et al'., 1972) and cefoxitin
(Dalen&Vree, 1980).
The elimination half-life of cefotiam increased only moderately with the degree
of renal dysfunction. This may be explained by the high contribution of non-renal
elimination processes to the overall elimination of cefotiam.
Cefotiam in renal failure 617
2 4 6 8
Creotinine clearance (l/h)
Figure 4. Correlation between renal clearance of cefotiam and creatinine clearance after administration
of 1 g iv single doses to normal subjects and patients with renal dysfunction.;C7r=O-7 C/''4-r=0-993'
/>< 0-001. CT
Despite the rapid elimination of cefotiam, urinary concentrations remained
several times higher than the minimal inhibitory concentrations (MIC) (Zak et al,
1979) for most organisms sensitive to this cephalosporin up to 24 h post-injection
in 14 patients. They ranged from 8-5 to 240 umol/1 in the 12-24 h urine fractions.
In two patients (case nos 5 and 14), they were above the MIC up to 7 h after dosing.
In adults with normal renal function, the dosage generally used is 1 g cefotiam
twice daily for mild to moderately severe infections. The daily dose can be raised
to 4g for more severe infections (Ishigami et al, 1979; Saito & Matsumoto, 1981;
Shiraha, Kawabata & Yura, 1979; Veyssier, Aubert & Carbon, 1981). This dosage
regimen may be adjusted in presence of severe renal failure to avoid accumulation
of cefotiam. For drugs with short serum half-lives such as cefotiam, it is better to
reduce the dose than to prolong the dosing interval (Fabre & Balant, 1976). The dose
can be reduced either to reach the same maximum plasma levels in subjects with
normal and with impaired renal function, or to obtain the same amount of drug in
the body during one dosage interval. The former approach is recommended for
bactericidal agents as the dosage regimen resulting in identical areas under the
plasma concentration-time curve may lead to concentrations below the bactericidal
range (Dettli, 1976; Fabre & Balant, 1976). The cefotiam maintenance dose was
consequently calculated to reach in each patient the same steady-state C ^ value
as in a subject with normal renal function. The individual reductions of the dose
calculated permitted to classify the patients in two groups as shown in Table II.
For moderate infections, the treatment, 1 g twice daily, can be used without
modification even in the presence of severe renal failure.
For severe infections, the dose must be reduced only for patients with C/CT< 1 1/h
and when the dose has to be given at dosing intervals less than 12 h. If the dose is
618 M. C. Rouan et al.
Table II. Dosing schedule for cefotiam in renal insufficiency (iv
doses expressed in % of that which should be given to a subject
with normal renal function)
Dosing
interval
(h)
6
8
12
*17 ml/min.
Moderate renal
insufficiency
(Ck> 1 1/h*)
100
loading
100
100
Severe renal
insufficiency
(C4r<l 1/h*)
dose maintenance dose
75
75
100
given every 6 or 8 h, the dose should be reduced to 75% of that to be given to a
subject with normal renal function. The loading dose should not be reduced in order
to achieve rapidly steady-state plasma concentrations.
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